ArticleHaematologica2026

Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: realworld efficacy and risks of early ponatinib dose reduction.

Jae-Ho Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.